Clinical trial · Observational
Mechanisms of Ischemic Stroke in Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to better understand the causes of stroke in people with cancer. Active cancer increases the risk of stroke. The investigators do not know exactly why this occurs but one possible reason is that people with cancer may have thicker blood than people without cancer. Thick blood can sometimes cause blood clots to form in the heart, which can then travel to the brain and cause stroke. This study is being done to help figure out why this and other causes of stroke occur in people with cancer. The investigators expect that information from this study will help doctors to more effectively prevent and treat stroke in individuals with cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Stroke | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood tests | Other | — | UNRESOLVED |
| Transcranial Doppler Microemboli Detection Study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Group 1: Cancer and Stroke
- description
- Patients with active solid tumor cancer and acute ischemic stroke. Will undergo blood tests and transcranial Doppler microemboli detection study.
- interventionNames
- Other: Blood tests
- Other: Transcranial Doppler Microemboli Detection Study
- label
- Group 2: Stroke and No Cancer
- description
- Patients with acute ischemic stroke and no cancer. Will undergo blood tests and transcranial Doppler microemboli detection study.
- interventionNames
- Other: Blood tests
- Other: Transcranial Doppler Microemboli Detection Study
- label
- Group 3: Cancer and No Stroke
- description
- Patients with active solid tumor cancer and no stroke. Will undergo blood tests and transcranial Doppler microemboli detection study.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria * 18 years of age or older * Active solid tumor cancer (for Groups 1 and 3 only) * MRI confirmed acute ischemic stroke (for Groups 1 and 2 only) * Available for blood draw at 96 hours (+/- 24 hours) from last known well time (for Groups 1 and 2 only) or within 2 weeks of enrollment (for Group 3) * Available for TCD within 2 weeks of enrollment Exclusion Criteria * Primary brain tumor or hematological cancer * Treatment with intravenous or intraarterial thrombolysis or mechanical embolectomy * Platelets \< 50,000/mm3 * Hemodialysis within 14 days * Active pregnancy * Infection within 14 days per Infectious Diseases Society of America (IDSA) criteria
References
Publications (1)
- DERIVEDNavi BB, Mathias R, Sherman CP, Wolfe J, Kamel H, Tagawa ST, Saxena A, Ocean AJ, Iadecola C, DeAngelis LM, Elkind MSV, Hull H, Jickling GC, Sharp FR, Ander BP, Stamova B. Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile. Stroke. 2019 Nov;50(11):3259-3264. doi: 10.1161/STROKEAHA.119.026143. Epub 2019 Sep 12. PMID 31510897